CD-19 Antibody Market Size Forecasted To Achieve 2.69 Billion By 2029 With Steady Growth

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the CD-19 Antibody Market Size and Projected Growth Rate?
The market size for the CD-19 antibody has seen a robust growth lately. It is projected that the market will expand from $1.75 billion in 2024 to $1.91 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 9.3%. The previous growth rate could be due to the growing incidences of B-cell malignancies, advancements in immunotherapy, heightened funds for oncology research, the advent of CAR-T cell therapies, increased health consciousness, and broader implementation of personalized medicine.

In the upcoming years, the CD-19 antibody market is projected to experience impressive growth, expanding to $2.70 billion by 2029 at a 9.0% Compound Annual Growth Rate (CAGR). Factors spurring this growth during the predictive period include the rising demand for specific cancer treatments, increasing use of clever cell therapies, growing instances of hematologic malignancies, larger healthcare access in emerging economies, and substantial improvements in current immunotherapies and biomanufacturing technologies. Trends anticipated to dominate this interval incorporate progress in antibody-drug combinations, the creation of bispecific antibodies, the inclusion of AI in antibody formulation, enhancements to cell therapy platforms, the adoption of single-use bioreactors, the introduction of nanobody-centered treatments, and heightened automation in the production of biologics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130

What Are the Major Segments in the CD-19 Antibody Market?
The CD-19 antibody market covered in this report is segmented -

1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
2) By Type: Polyclonal, Monoclonal
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications

Subsegments:
1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma
2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL
3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL
4) By Other Disease Types: Hairy Cell Leukemia, Waldenström's Macroglobulinemia, Marginal Zone Lymphoma

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp

What Are The Driving CD-19 Antibody Market Evolution?
The CD-19 antibody market's escalation is anticipated to be driven by an increasing frequency of B-cell malignancies. These are a variety of cancers that initiate from anomalous B lymphocytes, including conditions like B-cell lymphomas and leukemias, that impact the immune system and could trigger uncontrolled cell growth. Factors such as aging demographics, genetic influences, environmental interactions, lifestyle, better detection methods, and changes in the immune system are all attributed to the surge in B-cell malignancies. By explicitly targeting the CD19 protein on malignant B cells, the CD19 antibody contributes to the treatment of B-cell malignancies, leading to their elimination without harming healthy cells and bolstering the body's immune response. For example, according to the American Cancer Society, a non-profit organization based in the US, it was projected that around 80,620 individuals would be diagnosed with non-Hodgkin lymphoma in the USA in January 2024. Furthermore, an estimated 20,240 people, consisting of 44,590 males and 36,030 females, are likely to succumb to non-Hodgkin lymphoma. Thus, the increase in B-cell malignancies is fuelling the growth of the CD-19 antibody market.

Which Firms Dominate The CD-19 Antibody Market Segments?
Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.

What Are the Major Trends Shaping the CD-19 Antibody Market?
Leading firms in the CD-19 antibody market are centring their efforts on technological advancements such as the application of genetically modified autologous T-cell immunotherapy for increased effectiveness in cancer treatments, especially in the case of hematologic malignancies. In this method of treatment, the patient's T cells are genetically altered to detect and counteract cancer cells, and these modified cells are then re-infused into the patient's body to intensify the immune reaction against the disease. For instance, Autolus Therapeutics plc, a biopharmaceutical company based in the US, received US FDA approval for AUCATZYL (obecabtagene autoleucel) in November 2024. This treatment is for adult patients suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The goal of this strategy is to diminish hyperactive T-cell activation, thus reducing toxicity while optimizing the survival of the therapeutic cells. This treatment is delivered through a split-dose infusion on the first and tenth day, and the dosage is determined on an individual basis after assessing the condition of the bone marrow prior to the treatment.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report

Which Is The Largest Region In The CD-19 Antibody Market?
North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the CD-19 Antibody Market?
2. What is the CAGR expected in the CD-19 Antibody Market?
3. What Are the Key Innovations Transforming the CD-19 Antibody Industry?
4. Which Region Is Leading the CD-19 Antibody Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.